Nuclear Medicine and Endocrine Oncology Department, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.
Clinic for Nuclear Medicine, University Hospital Essen, Essen, Germany.
Eur J Nucl Med Mol Imaging. 2018 May;45(5):846-859. doi: 10.1007/s00259-018-3947-x. Epub 2018 Feb 16.
The skeleton is the most common metastatic site in patients with advanced cancer. Pain is a major healthcare problem in patients with bone metastases. Bone-seeking radionuclides that selectively accumulate in the bone are used to treat cancer-induced bone pain and to prolong survival in selected groups of cancer patients. The goals of these guidelines are to assist nuclear medicine practitioners in: (a) evaluating patients who might be candidates for radionuclide treatment of bone metastases using beta-emitting radionuclides such as strontium-89 (Sr), samarium-153 (Sm) lexidronam (Sm-EDTMP), and phosphorus-32 (P) sodium phosphate; (b) performing the treatments; and
骨骼是晚期癌症患者中最常见的转移部位。疼痛是骨转移患者的主要医疗保健问题。骨靶向放射性核素选择性地积聚在骨骼中,用于治疗癌症引起的骨痛,并延长某些癌症患者群体的生存期。这些指南的目的是协助核医学从业者:(a) 评估可能适合使用β发射放射性核素(如锶-89(Sr)、钐-153(Sm)依替膦酸(Sm-EDTMP)和磷-32(P)磷酸钠)治疗骨转移的患者;(b) 进行治疗。